Literature DB >> 16093365

Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.

Mitchell E Taub1, Lalitha Podila, Diane Ely, Iliana Almeida.   

Abstract

Compounds known to modulate P-glycoprotein (P-gp) activity were evaluated in cell monolayers expressing P-gp for their effects on the secretory transport of P-gp substrates paclitaxel, vinblastine, and digoxin. Paclitaxel has been proposed to selectively interact with a binding site on P-gp that is distinct from the vinblastine and digoxin-binding site. Using Madin-Darby canine kidney (MDCK)-multidrug resistance-1 (MDR1), MDCK-wild-type (WT), and Caco-2 cell monolayers, the basal-to-apical (BL-AP) apparent permeability (Papp) of [3H]paclitaxel, [3H]vinblastine, and [3H]digoxin in the presence of various concentrations of a series of structurally diverse P-gp substrates and modulators of P-gp function were determined. MDCK-WT cell monolayers demonstrated active secretory transport of all P-gp substrate probes, although the sensitivity to inhibition by verapamil was lower than that demonstrated in MDCK-MDR1 cell monolayers. When evaluated as competitive inhibitors, several known P-gp substrates had no effect or only a slight modulatory effect on the BL-AP Papp of all probe substrates in MDCK-MDR1 cells. The secretory transport of P-gp substrates in MDCK-WT cells was more sensitive to inhibition by known P-gp modulators compared with MDCK-MDR1 cells. Low concentrations of ketoconazole (1-3 microM) activated the BL-AP Papp of [3H]vinblastine and [3H]digoxin in MDCK-MDR1 cells but not in MDCK-WT or Caco-2 cells. Determination of secretory transport in P-gp expressing cell monolayers, such as MDCK-MDR1 and Caco-2, may be complicated by substrate cooperativity and allosteric binding, which may result in the activation of P-gp. In addition, expression of other efflux transporters in these cell lines introduces additional complexity in distinguishing which transporter is responsible for substrate recognition and transport.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16093365     DOI: 10.1124/dmd.105.005421

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  29 in total

1.  Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2.

Authors:  Tasha K Ritchie; Hyewon Kwon; William M Atkins
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition.

Authors:  J Cory Kalvass; Gary M Pollack
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

3.  Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination.

Authors:  Donna A Volpe; Salaheldin S Hamed; Lei K Zhang
Journal:  AAPS J       Date:  2013-12-13       Impact factor: 4.009

4.  Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy.

Authors:  Hua Lv; Xiaoping Zhang; Jyoti Sharma; M V Ramana Reddy; E Premkumar Reddy; James M Gallo
Journal:  AAPS J       Date:  2012-11-22       Impact factor: 4.009

5.  Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues.

Authors:  Hua Lv; Fan Wang; M V Ramana Reddy; Qingyu Zhou; Xiaoping Zhang; E Premkumar Reddy; James M Gallo
Journal:  Invest New Drugs       Date:  2012-03-01       Impact factor: 3.850

6.  Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.

Authors:  Konstantin Kuteykin-Teplyakov; Carlos Luna-Tortós; Kamila Ambroziak; Wolfgang Löscher
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

7.  Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein.

Authors:  Lora D Weidner; King Leung Fung; Pavitra Kannan; Janna K Moen; Jeyan S Kumar; Jan Mulder; Robert B Innis; Michael M Gottesman; Matthew D Hall
Journal:  Drug Metab Dispos       Date:  2015-12-10       Impact factor: 3.922

8.  P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents.

Authors:  Fionn E O'Brien; Richard M O'Connor; Gerard Clarke; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Neuropsychopharmacology       Date:  2013-05-14       Impact factor: 7.853

9.  Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies.

Authors:  Carlo Ballatore; Edward Hyde; Robert F Deiches; Virginia M-Y Lee; John Q Trojanowski; Donna Huryn; Amos B Smith
Journal:  Bioorg Med Chem Lett       Date:  2007-04-25       Impact factor: 2.823

10.  Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models.

Authors:  Yu-hua Li; Hui-chang Bi; Ling Huang; Jing Jin; Guo-ping Zhong; Xu-nian Zhou; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2013-12-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.